Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389493 · ClinicalTrials.gov registry record · NA
Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder
A NA study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT00389493 is a NA study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 100 participants.
The verdict
NCT00389493, a NA study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will compare the short- and long-term effectiveness of two common therapies in improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive disorder.
Interventions
- DRUG Placebo
- DRUG Risperidone
- BEHAVIORAL Exposure/ritual prevention therapy (EX/RP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-10 |
| Est. Completion | 2012-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389493
The ClinicalTrials.gov registry entry for NCT00389493 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00389493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389493 about?
NCT00389493 is a clinical study titled "Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder". This study will compare the short- and long-term effectiveness of two common therapies in improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive disorder.
What is the current status of trial NCT00389493?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2006-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00389493?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), Exposure/ritual prevention therapy (EX/RP) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00389493?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.